Table 4. Predictors of AKI after TAVR procedure.
Variable | Univariable Analysis | Multivariable Analysis | ||
---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age, year | 1.02 (0.99–1.05) | 0.06 | 1.03 (1.00–1.05) | 0.033 |
Male sex | 0.83 (0.59–1.17) | 0.29 | - | - |
NYHA class III/IV | 0.99 (0.63–1.56) | 0.95 | - | - |
Diabetes | 0.17 (0.82–1.69) | 0.38 | - | - |
Hypertension | 1.71 (0.13–2.59) | 0.011 | 1.69 (1.11–2.57) | 0.014 |
COPD | 0.90 (0.58–1.40) | 0.65 | - | - |
Pulmonary hypertension | 0.94 (0.63–1.40) | 0.75 | - | - |
CAD | 0.99 (0.69–1.40) | 0.93 | - | - |
Peripheral vascular disease | 1.07 (0.68–1.69) | 0.77 | - | - |
Previous CABG | 0.74 (0.48–1.15) | 0.18 | - | - |
STS score, % | 1.00 (0.97–1.02) | 0.98 | - | - |
eGFR, mL/min/1.73m2 | 1.01 (0.99–1.02) | 0.008 | 1.01 (1.00–1.02) | 0.053 |
Diuretics | 1.15 (0.80–1.64) | 0.44 | - | - |
ACE inhibitors or ARB | 1.11 (0.79–1.57) | 0.54 | - | - |
Beta-blockers | 0.93 (0.65–1.34) | 0.66 | - | - |
Statin | 1.22 (0.86–1.74) | 0.26 | - | - |
LVEF, % | 1.00 (0.99–1.01) | 0.28 | - | - |
Mean transaortic gradient, mmHg | 1.00 (0.99–1.01) | 0.97 | - | - |
AVA, cm2 | 0.71 (0.26–1.87) | 0.49 | - | - |
Contrast media volume, mL | 0.99 (0.99–1.00) | 0.60 | - | - |
Non-transfemoral access | 0.93 (1.00–3.73) | 0.048 | 2.07 (1.06–4.07) | 0.034 |
Prosthetic valve type | - | 0.62 | - | - |
Corevalve | 1.00 | - | - | - |
Sapien XT | 0.90 (0.60–1.36) | - | - | - |
Inovare prosthesis | 1.46 (0.56–3.77) | - | - | - |
Period of TAVR procedure | 0.23 | - | - | |
T1 (2008–2010) | 1.00 | - | - | - |
T2 (2011–2013) | 0.73 (0.47–1.15) | - | - | - |
T3 (2014–2015) | 0.63 (0.36–1.08) | - | - | - |
95% CI, 95% confidence interval.
Abbreviations: ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; ARB, angiotensin receptor blocker; AVA, aortic valve area; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OR, odds ratio; STS, Society of Thoracic Surgeons. TAVR, transcatheter aortic valve replacement.